Renowned physician, Dr. Apollo, discloses the ideal cooking oil for individuals struggling with excess weight and elevated cholesterol levels.
The quality of cooking oil used in daily meals plays a significant role in maintaining overall health, particularly heart wellness and cholesterol balance. Dr. Sudhir Kumar, a senior doctor at Apollo Hospitals, Hyderabad, recently shared insights on the benefits of using rice bran oil over sunflower oil in Indian kitchens. According to Dr. Kumar, rice bran oil is a better option for routine Indian cooking due to its well-rounded mix of fats, including monounsaturated and polyunsaturated fatty acids, which support cardiovascular health.
Rice bran oil has several advantages, including its ability to withstand high cooking temperatures without breaking down easily, making it suitable for frying, sautéing, and tadka preparations. It also contains natural compounds that may help reduce LDL or bad cholesterol levels, making it a heart-friendly choice for long-term use. On the other hand, sunflower oil, while popular, has limitations when used regularly. It is rich in omega-6 fatty acids, which can disturb the body’s fat balance and promote inflammation when consumed in excess. Additionally, sunflower oil has lower resistance to heat, which can cause it to degrade faster and reduce its nutritional value.
The idea of rotating cooking oils every few months is not necessary, according to Dr. Kumar. Instead of focusing on constant changes, attention should be given to moderation and overall dietary balance. Using one or two reliable oils over an extended period is sufficient for most households. The key is to select an oil that handles heat well, use it sparingly, and maintain a balanced intake of fats. The quantity of oil consumed daily has a far greater impact on health than frequently replacing one oil with another.
In conclusion, choosing the right cooking oil is crucial for maintaining good health. Rice bran oil is a better option for Indian kitchens due to its thermal stability, heart-friendly properties, and balanced mix of fats. By prioritizing stability and restraint, individuals can make informed choices about their cooking oil and maintain a healthy diet. As a reliable and trusted news source, it is essential to provide accurate and unbiased information to help individuals make informed decisions about their health.
US Biosecure Act sparks China+1 opportunity for Indian contract development and manufacturing organizations (CDMOs), with Piramal Pharma anticipating significant long-term benefits.
The proposed US Biosecure Act, which aims to restrict certain biotech and pharmaceutical contracts involving China, could open up a significant opportunity for Indian contract development and manufacturing organizations (CDMOs) over the next few years. According to Nandini Piramal, Chairperson of Piramal Pharma, the Act could contribute to the broader push for reshoring of pharmaceutical supply chains in the US, creating potential opportunities for Indian manufacturers.
Although the Act is still in its early stages and has to pass through several legislative and regulatory processes, Piramal believes that it will take time to implement and have a meaningful financial impact. The Act includes a grandfathering clause of around five years, allowing companies to continue with existing contracts before being required to transition. This means that pharmaceutical companies will need to start planning relocations well before the deadline.
Piramal Pharma, with its existing manufacturing footprint in North America, is well-positioned to benefit from the potential opportunity. The company has seen an uptick in requests for proposals (RFPs) from US clients, although it’s too early for firm decisions or large-scale conversions. Piramal noted that the Chinese industry is still cheaper due to its scale, but even a partial shift of global pharma outsourcing away from China could be meaningful for Indian companies.
The financial impact of the Biosecure Act on Indian CDMOs is expected to emerge over the medium term, with Piramal estimating it to be around three to five years. The potential upside from the Act reinforces the longer-term China+1 thesis for Indian pharma manufacturing, even as companies and investors wait for greater legislative clarity and tangible order wins.
Piramal also noted that the industry is aware of the potential changes and is preparing for them, but it’s too early to commit definitively. The company has seen some funding uptick in the US biotech sector, but it’s still muted optimism, and decisions are being made, but it’s too soon to commit definitively.
In terms of the company’s performance, Piramal stated that they can stick to their guidance of flat revenue growth and margins likely to be in the moderate to low teens for the year. However, some of these decisions will take time to show up in the P&L, and it’s too early for a decision. Overall, the proposed US Biosecure Act presents a potential opportunity for Indian CDMOs, and Piramal Pharma is well-positioned to benefit from it.
Does Investing in NATCO Pharma (NSE:NATCOPHARM) Come with Significant Risks?
The article discusses the importance of considering debt when assessing a company’s risk, as stated by Charlie Munger, a renowned investor. Li Lu, a fund manager backed by Berkshire Hathaway, emphasizes that the biggest investment risk is not price volatility, but the potential for permanent loss of capital, often caused by debt. The article then examines the debt levels of NATCO Pharma Limited, an Indian pharmaceutical company.
As of September 2025, NATCO Pharma had ₹2.53 billion in debt, up from ₹2.01 billion a year ago. However, the company also has ₹32.0 billion in cash, resulting in a net cash position of ₹29.5 billion. The company’s liabilities, including short-term and long-term debt, total ₹17.0 billion, which is offset by its cash and receivables valued at ₹17.3 billion.
The article concludes that NATCO Pharma’s debt levels are manageable, given its significant cash reserves and ability to generate free cash flow. The company’s free cash flow over the past three years has been around 63% of its earnings before interest and tax (EBIT), which is a normal level. This suggests that NATCO Pharma is in a good position to pay down debt when necessary.
While the company’s debt levels are not a major concern, the article notes that falling earnings could potentially make its debt more risky. The company’s EBIT declined by 32% over the last year, which could impact its ability to maintain a healthy balance sheet.
Overall, the article suggests that NATCO Pharma’s debt levels are not a significant concern, given its strong cash position and ability to generate free cash flow. However, investors should continue to monitor the company’s earnings and debt levels to ensure that they remain manageable. The article also notes that there are other risks associated with investing in NATCO Pharma, including two warning signs that investors should be aware of.
In conclusion, the article provides a detailed analysis of NATCO Pharma’s debt levels and financial position, highlighting the importance of considering debt when assessing a company’s risk. While the company’s debt levels are manageable, investors should remain vigilant and monitor the company’s earnings and debt levels to ensure that they remain healthy.
Apollo Hospital cardiac surgeon sets the record straight on palm oil, saying ‘it’s healthy in moderation, despite common misconceptions’.
Palm oil has been a topic of debate when it comes to health, with several misconceptions surrounding its use. To dispel these myths, Dr. Varun Bansal, a senior consultant cardiac surgeon at Indraprastha Apollo Hospitals, shared his insights on the common misconceptions surrounding palm oil. Here are the five major myths debunked:
- Palm oil is unhealthy: Dr. Bansal emphasizes that palm oil can be a safe choice when used wisely and as part of a balanced diet. It is a versatile and stable cooking oil with a high smoke point and longer shelf life.
- Palm oil contains cholesterol: This myth is mistaken, as palm oil is 100% cholesterol-free, like all vegetable oils. It is the overall diet, not the oil alone, that determines cholesterol levels.
- Palm oil harms the heart and increases the risk of heart disease: Dr. Bansal cites a review from the World Journal of Cardiology, which found that palm oil can actually protect the heart and blood vessels due to its antioxidant properties. Eating it as part of a normal, balanced diet does not increase the risk of heart disease.
- Palm oil is carcinogenic: Dr. Bansal debunks this myth, stating that the concerns arise only when oils are repeatedly overheated or reused, which can form harmful compounds. This risk is common to all cooking oils.
Dr. Bansal notes that palm oil can be used for sautéing, frying, baking, or seasoning, and is thermally stable, making it ideal for Indian cooking. He recommends using 2-3 tablespoons per person per day (from all oils combined) and suggests using palm oil alongside other oils like mustard, coconut, or olive to balance fatty acid intake.
In conclusion, palm oil can be a healthy choice when consumed as part of a balanced diet. It is essential to use it wisely and in moderation, just like any other cooking oil. By debunking these common myths, Dr. Bansal aims to educate people about the benefits and safe use of palm oil.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.